ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
NewLink wields ax, clearing the way for leaner IDO program
August 02, 2018NewLink has cut its headcount by a third to buy the time it needs to prove that—despite setbacks—its IDO inhibitor indoximod is still worth pursuing. -
Roche pens death notice for NewLink IDO/TDO cancer collaboration
May 16, 2018Just a few weeks out from ASCO, and with more than a touch of inevitability, Roche is axing its IDO/TDO inhibitor work “in its entirety” with partner NewLink Genetics as the fallout from a string of weak IDO trials across biopharma continues. -
Shareholder suit targets NewLink management over failed cancer vaccine trial
May 27, 2017A year after NewLink Genetics reported a phase 3 trial failure for its pancreatic cancer vaccine that crushed shares, a shareholder is taking it to the company’s current and former execs for “gross mismanagement” and other allegations.
Pharma Sources Insight January 2025
